
    
      Approximately 30 patients will be enrolled and receive the following treatments:

      TACE (day 1, up to twice. TACE interval will be 4～6 weeks) → Ablation (4 weeks after the last
      TACE, up to twice. Ablation interval will be 4～6 weeks) → Durvalumab (at least 1 week after
      the last ablation, 1500 mg Q4W, until mRECIST criteria defined radiological progression or
      other discontinuation criteria were met, but no more than 1 year).
    
  